SBH
LLY icon

Segall Bryant & Hamill’s Eli Lilly LLY Stock Holding History

Segall Bryant & Hamill’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,241
Closed -$8.46M – 605
2025
Q1 		$8.46M Sell
10,241
-1,176
-10% -$979K 0.13% 242
2024
Q4 		$8.81M Hold
11,417
– – 0.12% 244
2024
Q3 		$10.1M Buy
+11,417
New +$10.3M 0.14% 231
2023
Q4 		– Sell
-12,472
Closed -$6.7M – 410
2023
Q3 		$6.7M Sell
12,472
-47
-0.4% -$24.2K 0.08% 274
2023
Q2 		$5.87M Sell
12,519
-505
-4% -$212K 0.06% 314
2023
Q1 		$4.47M Buy
13,024
+193
+2% +$65.1K 0.05% 352
2022
Q4 		$4.69M Sell
12,831
-86
-0.7% -$30.5K 0.05% 336
2022
Q3 		$4.18M Sell
12,917
-202
-2% -$64K 0.05% 341
2022
Q2 		$4.25M Sell
13,119
-66
-0.5% -$19.8K 0.05% 346
2022
Q1 		$3.77M Sell
13,185
-616
-4% -$159K 0.04% 373
2021
Q4 		$3.81M Sell
13,801
-250
-2% -$63.4K 0.04% 353
2021
Q3 		$3.25M Buy
14,051
+655
+5% +$162K 0.03% 407
2021
Q2 		$3.08M Buy
13,396
+250
+2% +$50.2K 0.03% 420
2021
Q1 		$2.46M Sell
13,146
-316
-2% -$61.8K 0.02% 449
2020
Q4 		$2.28M Buy
13,462
+325
+2% +$48.5K 0.03% 411
2020
Q3 		$1.95M Buy
13,137
+2,000
+18% +$310K 0.03% 390
2020
Q2 		$1.83M Sell
11,137
-803
-7% -$123K 0.03% 348
2020
Q1 		$1.66M Sell
11,940
-400
-3% -$55K 0.03% 362
2019
Q4 		$1.62M Sell
12,340
-69
-0.6% -$8K 0.03% 431
2019
Q3 		$1.39M Hold
12,409
– – 0.02% 473
2019
Q2 		$1.38M Sell
12,409
-910
-7% -$107K 0.02% 475
2019
Q1 		$1.73M Buy
13,319
+510
+4% +$62K 0.03% 433
2018
Q4 		$1.48M Sell
12,809
-185
-1% -$20.7K 0.03% 450
2018
Q3 		$1.39M Sell
12,994
-32
-0.2% -$3.2K 0.02% 499
2018
Q2 		$1.11M Buy
13,026
+2,618
+25% +$215K 0.02% 520
2018
Q1 		$805K Hold
10,408
– – 0.02% 376
2017
Q4 		$879K Buy
10,408
+533
+5% +$45.4K 0.02% 356
2017
Q3 		$845K Buy
9,875
+27
+0.3% +$2.21K 0.02% 376
2017
Q2 		$810K Hold
9,848
– – 0.02% 379
2017
Q1 		$828K Hold
9,848
– – 0.02% 369
2016
Q4 		$724K Buy
9,848
+543
+6% +$40.4K 0.02% 380
2016
Q3 		$747K Sell
9,305
-150
-2% -$12K 0.02% 369
2016
Q2 		$745K Hold
9,455
– – 0.02% 380
2016
Q1 		$681K Hold
9,455
– – 0.02% 386
2015
Q4 		$797K Buy
9,455
+200
+2% +$16.6K 0.02% 358
2015
Q3 		$775K Hold
9,255
– – 0.02% 369
2015
Q2 		$773K Sell
9,255
-100
-1% -$7.62K 0.02% 370
2015
Q1 		$680K Hold
9,355
– – 0.02% 383
2014
Q4 		$645K Buy
9,355
+844
+10% +$57K 0.01% 393
2014
Q3 		$552K Buy
8,511
+3,150
+59% +$199K 0.01% 416
2014
Q2 		$333K Sell
5,361
-300
-5% -$17.9K 0.01% 486
2014
Q1 		$333K Sell
5,661
-500
-8% -$27.9K 0.01% 499
2013
Q4 		$314K Sell
6,161
-580
-9% -$29K 0.01% 509
2013
Q3 		$339K Buy
6,741
+800
+13% +$41.9K 0.01% 493
2013
Q2 		$292K Buy
+5,941
New +$323K 0.01% 479

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Segall Bryant & Hamill's LLY Position: Q2 2025 in Review

Segall Bryant & Hamill sold out of Eli Lilly (LLY) in Q2 2025, closing a stake of 10,241 shares — an estimated $8.46M sold.

Segall Bryant & Hamill first reported a position in LLY in Q2 2013 and held it in 45 quarters. The position peaked at $10.1M in Q3 2024. 3,906 funds tracked by Wall St. Rank hold LLY as of Q2 2025.

  • Segall Bryant & Hamill reported no remaining Eli Lilly position as of Q2 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 10,241 Eli Lilly shares in Q2 2025, an estimated $8.46M.
  • Segall Bryant & Hamill first reported a position in Eli Lilly in Q2 2013 and held it in 45 quarters.
  • Segall Bryant & Hamill's Eli Lilly position peaked at $10.1M in Q3 2024.
  • 3,906 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2025.

Based on Segall Bryant & Hamill's 13F filing for Q2 2025, filed 12 Aug 2025.